bioMérieux Receives FDA Approval for THxIDTM-BRAF Companion Diagnostic Test
30 Mai, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its novel molecular test THxIDTM-BRAF received PMA* approval from the FDA (Food and Drug Administration) for commercialization in the United States. This unique test is intended for the qualitative and simultaneous detection of both BRAF V600E and V600K mutations in late stage metastatic melanoma tumor samples.
VIDAS® 3, the New-generation VIDAS® Presented at the JIB International Biologists Congress
07 November, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, presented today VIDAS® 3, the new generation of its automated immunoassay system, during the Journées Internationales de Biologie (JIB) congress in Paris. This latest enhancement to the VIDAS® range offers major new features including, increased automation and greater traceability.
bioMérieux Completes its VIDAS® Hepatitis Panel with a New Test for the Diagnosis of Hepatitis C
03 Mai, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of VIDAS® Anti-HCV for the detection of the hepatitis C virus (HCV). With this new CE marked test, VIDAS® now has a complete hepatitis menu with tests for A, B and C viral hepatitis.
